# Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

> **NCT00687596** · PHASE2 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** TAC-101
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00687596
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08-01
- **Primary completion:** 2010-05-10
- **Final completion:** 2010-05-10
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** Terminated due to safety concerns
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687596, "Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00687596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*